Source: China News Service / CCTV News Client
China’s Pharmaceutical Cold Chain Enters a More Structured Growth Phase
What Happened
China News Service, citing CCTV News Client, reported that the China Federation of Logistics & Purchasing released the China Pharmaceutical Logistics and Supply Chain Development Report 2026 on May 22, 2026. According to the report, China’s pharmaceutical logistics system is becoming more complete, while pharmaceutical cold chain logistics is entering a faster growth stage.
The report estimates that China’s pharmaceutical distribution market reached RMB 2.963 trillion in 2025, up 0.54% year on year. Total pharmaceutical logistics expenses were estimated at RMB 101.99 billion, up 1.03% year on year. Pharmaceutical cold chain logistics expenses were estimated at RMB 26.78 billion, up 1.96% year on year.
How It Works
The report indicates that China has formed a modern pharmaceutical logistics system built around logistics centers, warehousing infrastructure, transportation vehicles, and information systems. This matters because pharmaceutical cold chain performance depends on integrated infrastructure, not isolated equipment.
Transport capacity is also improving. In 2025, China’s pharmaceutical industry had an estimated 46,430 self-owned vehicles, up 1.5% year on year. Among them, refrigerated vehicles reached 16,175 units, up 2.8% year on year. Road transport remains the primary mode, covering both trunk transportation and urban distribution, while air and rail provide supplementary capacity.
From a cold chain operations perspective, this structure suggests that China’s medical cold chain is moving toward a more layered network: pharmaceutical logistics centers provide storage and consolidation, refrigerated vehicles support trunk and city distribution, information systems support traceability, and air or rail capacity can be used for higher-value or time-sensitive lanes.
Why It Matters
Pharmaceutical cold chain logistics is becoming more important as China’s healthcare market handles more vaccines, biologics, specialty medicines, diagnostics, and other temperature-sensitive medical products. These products require stable temperature control, documented handling, shipment visibility, and deviation management.
The increase in refrigerated vehicle capacity is especially relevant for domestic distribution. Urban delivery and regional trunk transport are frequent risk points because products may move through multiple handoffs, loading docks, vehicles, pharmacies, hospitals, and distribution centers. More dedicated refrigerated fleet capacity can help reduce temperature excursion risk if combined with proper SOPs, calibrated monitoring, and route control.
The report also reflects a broader industry trend: medical logistics is no longer just a cost center. It is becoming part of product quality assurance, market access, and healthcare supply continuity.
B2B Impact
For pharmaceutical distributors and healthcare logistics providers, the report points to continued demand for GDP-aligned warehousing, refrigerated transport, validated handling workflows, temperature monitoring, and digital traceability.
For cold chain packaging suppliers, China’s expanding pharmaceutical cold chain creates opportunities for validated passive shippers, reusable insulated containers, PCM systems, temperature-controlled totes, and last-mile packaging solutions for hospital, pharmacy, and specialty-drug distribution.
For monitoring and software companies, the development of information systems creates demand for shipment-level visibility, route-level temperature data, exception alerts, inventory traceability, and compliance reporting.
For B2B cold chain solution providers, the key takeaway is that China’s pharmaceutical cold chain is becoming more structured and infrastructure-driven. The strongest market opportunities will likely sit at the intersection of refrigerated transport, compliant warehousing, validated packaging, monitoring data, and digital supply chain control.